(Q38895976)

7 September 2017

title

Class IIa HDAC inhibition enhances ER stress-mediated cell death in multiple myeloma (English)

1 reference

7 September 2017

1 reference

S Kikuchi

1

1 reference

7 September 2017

R Suzuki

2

1 reference

7 September 2017

H Ohguchi

3

1 reference

7 September 2017

Y Yoshida

4

1 reference

7 September 2017

D Lu

5

1 reference

7 September 2017

F Cottini

6

1 reference

7 September 2017

J Jakubikova

7

1 reference

7 September 2017

G Bianchi

8

1 reference

7 September 2017

T Harada

9

1 reference

7 September 2017

G Gorgun

10

1 reference

7 September 2017

Y-T Tai

11

1 reference

7 September 2017

P G Richardson

12

1 reference

7 September 2017

T Hideshima

13

1 reference

7 September 2017

K C Anderson

14

1 reference

7 September 2017

publication date

24 March 2015

1 reference

7 September 2017

1 reference

7 September 2017

volume

29

1 reference

7 September 2017

issue

9

1 reference

7 September 2017

page(s)

1918-1927

1 reference

https://scigraph.springernature.com/pub.10.1038/leu.2015.83

7 September 2017

exact match

0 references

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.83

Improved survival in multiple myeloma and the impact of novel therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.83

New strategies in the treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.83

Anticancer activities of histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.83

Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.83

PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.83

Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.83

A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.83

A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.83

Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.83

Class II histone deacetylases: versatile regulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.83

Lysine acetylation targets protein complexes and co-regulates major cellular functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.83

Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.83

Histone deacetylase 9 (HDAC9) regulates the functions of the ATDC (TRIM29) protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.83

HDAC5, a key component in temporal regulation of p53-mediated transactivation in response to genotoxic stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.83

Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.83

Class IIa histone deacetylases: regulating the regulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.83

Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.83

HDAC4 mediates transcriptional repression by the acute promyelocytic leukaemia-associated protein PLZF

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.83

Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.83

Differential expression of HDAC3, HDAC7 and HDAC9 is associated with prognosis and survival in childhood acute lymphoblastic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.83

HDAC5 and HDAC9 in medulloblastoma: novel markers for risk stratification and role in tumor cell growth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.83

New directions in ER stress-induced cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.83

Regulated translation initiation controls stress-induced gene expression in mammalian cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.83

An integrated stress response regulates amino acid metabolism and resistance to oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.83

The double-stranded RNA-activated protein kinase PKR is dispensable for regulation of translation initiation in response to either calcium mobilization from the endoplasmic reticulum or essential amino acid starvation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.83

Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.83

Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.83

HDAC4 protects cells from ER stress induced apoptosis through interaction with ATF4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.83

Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.83

Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.83

Biologic sequelae of I{kappa}B kinase (IKK) inhibition in multiple myeloma: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.83

Transcriptome analysis reveals molecular profiles associated with evolving steps of monoclonal gammopathies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.83

Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.83

Plasma cell differentiation requires the transcription factor XBP-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.83

Plasma cell differentiation and the unfolded protein response intersect at the transcription factor XBP-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.83

ER stress and the unfolded protein response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.83

ER stress triggers apoptosis by activating BH3-only protein Bim

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.83

Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.83

Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.83

The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25801913

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Peroxisome proliferator-activated receptor γ is inhibited by histone deacetylase 4 in cortical neurons under oxidative stress

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25801913

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/LEU.2015.83

1 reference

Dimensions Publication ID

7 September 2017

1036218973

0 references

1 reference